Unknown

Dataset Information

0

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.

ABSTRACT:

SUBMITTER: Dorward J 

PROVIDER: S-EPMC10927299 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.

Dorward Jienchi J   Sookrajh Yukteshwar Y   Lessells Richard R   Bulo Elliot E   Bodley Nicola N   Singh Lavanya L   Moodley Pravikrishnen P   Samsunder Natasha N   Drain Paul K PK   Hayward Gail G   Butler Christopher C CC   Garrett Nigel N  

Journal of acquired immune deficiency syndromes (1999) 20240311 5

Similar Datasets

Unknown Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
| S-EPMC10691652 | biostudies-literature
Unknown Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
| S-EPMC10288006 | biostudies-literature
Unknown Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
| S-EPMC5063380 | biostudies-literature
Unknown Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis.
| S-EPMC8059266 | biostudies-literature
Unknown Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
| S-EPMC7494118 | biostudies-literature
Unknown Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.
| S-EPMC10059835 | biostudies-literature
Unknown Monocyte count predicts low-level viremia in people living with HIV receiving antiretroviral therapy: A retrospective cohort study.
| S-EPMC12611236 | biostudies-literature
Unknown Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
| S-EPMC8130017 | biostudies-literature
Unknown Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
| S-EPMC3203388 | biostudies-literature
Unknown Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy.
| S-EPMC7031902 | biostudies-literature